WNT16 and Osteopenia: Diabetic patients have higher risk of fracture; the reduction in Wnt16 expression and mediated canonical Wnt signalling activity in cortical bone in diabetic environment might be responsible for the osteopenia, and activating Wnt16/β‐catenin pathway improves the bone strength and provides a therapeutic opportunity for the treatment of osteopenia in diabetic patients.133